Cogent Biosciences Inc (COGT) Actualités

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT...

Cogent Biosciences to Participate in the Guggenheim Biotech Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

•   Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025...

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT...